Cargando…
The DLC-1 tumor suppressor is involved in regulating immunomodulation of human mesenchymal stromal /stem cells through interacting with the Notch1 protein
BACKGROUND: Immunomodulatory activities of human mesenchymal stromal /stem cells (hMSCs) has been widely recognized as the most critical function of hMSCs for exerting its therapeutic effects. However, the detailed mechanisms responsible for regulating the immunomodulation of hMSCs still remain larg...
Autores principales: | Na, Tao, Zhang, Kehua, Yuan, Bao-Zhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640439/ https://www.ncbi.nlm.nih.gov/pubmed/33148199 http://dx.doi.org/10.1186/s12885-020-07542-5 |
Ejemplares similares
-
The Notch Signaling Regulates CD105 Expression, Osteogenic Differentiation and Immunomodulation of Human Umbilical Cord Mesenchymal Stem Cells
por: Na, Tao, et al.
Publicado: (2015) -
DLC-1:a Rho GTPase-activating protein and tumour suppressor
por: Durkin, Marian E, et al.
Publicado: (2007) -
DLC1: a tumor suppressor that regulates Rho signaling
por: Tripathi, Brajendra K., et al.
Publicado: (2017) -
CDK5 is a major regulator of the tumor suppressor DLC1
por: Tripathi, Brajendra K., et al.
Publicado: (2014) -
The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1
por: Sanchez-Solana, Beatriz, et al.
Publicado: (2021)